CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: biowa who wrote (414)	12/2/1999 10:26:00 AM
From: Bob L	Read Replies (1) of 666

<<Zevalin is given in a dosage independent of dosimetry in the PIII isn't it? >> It doesn't exactly look like it from the phase III protocol I downloaded from NIC PDQ some time ago: "Patients receive rituximab IV immediately followed by an imaging dose of IDEC-In2B8 IV over 10 minutes on day 1. Patients meeting the dosimetry requirements receive rituximab IV over several hours and IDEC-Y2B8 IV over 10 minutes on day 8." But I don't know what they mean by "meeting the dosimetry requirements." Maybe that just means they can measure the distribution and estimate the radiation dose to various organs as a monitoring thing rather than using dosimetry to estimate the dose. Maybe they need a different word than "dosimetry."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next